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Prostate cancer (PCa) is the second most common cancer
in men and an estimated 1.1 million men worldwide were
diagnosed with prostate cancer in 2012 with almost 70%
of the cases occurring in more developed regions [1]. With
an estimated 307.00 deaths in 2012, prostate cancer is the
fifth leading cause of death from cancer in men [1]. In
patients with elevated or rising prostate-specific antigen
(PSA) and/or abnormal digital rectal examination (DRE),
random systematic transrectal ultrasound (TRUS) guided
prostate biopsy is the most commonly used technique to
establish PCa diagnosis. However, PSA alone has a low
specificity for PCa detection [2] and several modifications
thatmay improve the specificity of PSA in PCa diagnosis have
been described such as age-specific reference ranges, free-
to-total PSA ratio, PSA velocity, PSA density, PSA transition
zone density, PSA molecular forms (PHI (prostate health
index) score (total PSA, free PSA, and p2PSA) and the
4Kscore, whichmeasures blood plasma levels of four different
prostate-derived kallikrein proteins: total PSA, free PSA,
intact PSA, and human kallikrein 2 (hK2)), and numerous
other novel biomarkers (PCA3, TMPRSS2-ERGGene fusion,
etc.).
Random systematic prostate sampling with TRUS guided
biopsy also has its inherent limitations. First of all, clinically
insignificant cancers are often identified by chance and
affect survival data due to lead and length time bias from
overdetection and overtreatment of indolent disease [3]. Sec-
ondly, systematic biopsies through random sampling error
may lead to incorrect risk stratification and may perform
poorly at documenting the exact extent and heterogeneity
of the disease [4]. Lastly, undersampling, particularly, when
prostate volume is taken into account, occurs in up to 30% of
cases with clinically significant tumors being missed (false-
negativity) on initial random systematic biopsy [5]. Efforts to
overcome these sampling errors include performing multiple
repeat randombiopsies or increasing the core number during
random or systematic template-guided transperineal satura-
tion biopsies. However, this approach results in a marginal
increase in the overall detection rate without increasing the
rate of significant cancer detection [6], while increasing cost
and morbidity significantly.
Imaging has always been problematic in respect to
PCa diagnosis and has been essentially limited to biplanar
transrectal ultrasound and its modifications. Technological
ultrasound developments with contrast enhancement and
3D reconfiguration have been underutilized by the uro-
logical community as a whole. Isotopic efforts with FDG
and 11-choline PET scans have also disappointed in terms
of diagnostic yield of prostatic disease. Recently, with the
advent of better technology and different sequences, mag-
netic resonance imaging (MRI) has shown to be able to
play a significant role in this respect. Numerous studies
have now indicated that multiparametric (Mp) prostate MRI
at 3 Tesla, including anatomical and functional sequences,
enables accurate PCa detection and local stagingwith reason-
able sensitivity and specificity [7]. Given that,Mp-MRImight
be useful in image-guided therapy such as focal therapy, as
well as in whole gland therapy such as radical prostatectomy
or modern techniques of external beam and interstitial
radiotherapy.
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Sensitivity for detecting larger (>5mm) andmore aggres-
sive (Gleason score > 7) tumors is better for Mp-MRI,
indicating that it may preferentially detect clinically relevant
tumors [8]. However, inmost studies histological correlations
were done using targeted or systematic ultrasound guided
biopsy samples and this does not represent a perfect coreg-
istration. Blinded multicenter studies that validate Mp-MRI
findings with biopsy and then whole-mount prostatectomy
histopathology are lacking. Only until these are done can
we determine Mp-MRI’s performance for detecting clinically
significant cancers in different prostate gland locations (cen-
tral zone, apical region, anterior peripheral zone, etc.).
In an effort to standardize the reporting of Mp-MRI
findings and to reduce subjectivity of image interpretation,
the PI-RADS (prostate imaging and reporting archiving data
system) classification has been developed. In this scoring
system every parameter (T2WI, DWI, DCE-MRI, andMRSI)
is scored on a five-point scale. Additionally, each lesion
is given an overall score, to predict its chance of being a
clinically significant cancer [9]. Nevertheless, given the fact
that the minimum and optimum requirements regarding
general MRI components andMRI sequence parameters and
techniques are not universally agreed upon, there remains
the “Achilles Heel” of considerable interobserver variation.
As a result, more prospective studies have to be executed in
order to validate the accuracy and interobserver variability of
multiparametric prostate imaging.
Mp-MRI represents a potential tool to address the lim-
itations of contemporary random systematic biopsy related
to undersampling and false-negativity. Among biopsy-naive
men, it increases the frequency of significant cancer detection
to 50% in low-risk (PSA < 10 ng/mL, normal DRE) and
71% in high-risk (PSA > 10 ng/mL, abnormal DRE) patients
[10]. In low-risk men, the negative predictive value of a
combination of low level of suspicion based on MRI with
prostate volume parameters was nearly 98% and thismight be
useful to avoid biopsy for those who will not need immediate
active treatment if diagnosed with prostate cancer [10] but
must compete on cost terms with novel blood-urine tests.
Among men with a previous negative TRUS guided random
biopsy but persistent clinical suspicion, 72% to 87%of cancers
detected by MRI guidance were clinically significant [11].
Among active surveillance candidates, repeat biopsy
using MRI targeting demonstrates high sensitivity in con-
firming low-risk disease in low suspicion score lesions and
risk upgrading in highly suspicious lesions [12].
Techniques of MRI targeted biopsy include visual cog-
nitive transrectal ultrasound guided biopsy, software coreg-
istered magnetic resonance imaging-ultrasound, transrectal
ultrasound guided biopsy, and in-bore magnetic resonance
imaging guided biopsy. While many studies have compared
targeted biopsy to systematic biopsy, few have evaluated the
cancer detection rates across different targeted techniques.
Fusion targeting seems to improve accuracy for smaller MRI
detected lesions as well as high-grade cancer (Gleason score>
7) [13]. However, the optimal method for MR targeted biopsy
remains in evolutionary flux and has yet to be established.
Mp-MRI is also a feasible and very useful tool in detecting
local recurrence in patients who have undergone radical
prostatectomy (RP) or radiotherapy. Concerning post-RP
local recurrences, DCE-MRI seems to be the most reliable
technique for detection, though DWI can be proposed as a
reliable alternative [14]. For predicting locally recurrent PCa
after radiation therapy, the use of combined T2WI and DWI
showed a better diagnostic performance compared to T2WI
alone [15].
Is Mp-MRI ready for prime time? Well, this question
remains open. Currently, the use of Mp-MRI as a “screening”
tool formen referred with abnormal PSA for biopsy decision-
making cannot be a general recommendation. However, it
will undoubtedly have a place alongside novel biomarkers
in diagnostic and surveillance strategies, in repeat biopsy
settings, and perhaps in surgical planning for nonmetastatic
bulky local disease as part of a planned multimodality
treatment regimen.
We hope that the readers of this special issue with 11
manuscripts which explores different aspects of Mp-MRI for
diagnosing and treating PCa in its different forms will find
some answers for different clinical settings. We are confident
that this very timely compilation will be a major reference for
many of us interested in prostate cancer.
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